Since miR-139 was found to downregulate CXCR4 and thus inhibit tumor cell aggressiveness both in vitro and in vivo, we next measured miR-139 levels in women diagnosed with invasive ductal carcinoma (IDC). Here, CXCR4 is linked to invasive ductal breast carcinoma.